Keytruda may offer new hope for cervical precancer
NCT ID NCT04712851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) can treat high-grade cervical precancer (CIN 2/3 or carcinoma in situ). The study will enroll 25 women and measure how many have a complete response at 6 months. The goal is to see if this drug can help the immune system clear abnormal cells without surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda)
- What this could lead to
- If successful, this could offer a non-surgical treatment option for high-grade cervical precancer, potentially reducing the need for surgery.
- What could go wrong
- This is a small, early-phase trial with only 25 participants. The drug may not work for everyone, and side effects from immunotherapy can occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California at Los Angeles / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a portable heat device match cryotherapy for cervical precancer?
- Could a blast of argon plasma wipe out cervical precancer without surgery?
- HPV DNA test could slash cervical cancer deaths in High-Risk populations
- Could a Light-Activated cream replace surgery for cervical precancer?
- Cervical surgery may alter blood flow to the uterus
- Enzyme-HPV link in cervical disease explored